期刊文献+

TGF-β诱导乳鼠上皮组织DNA甲基转移酶及相关miRNA表达的研究 被引量:1

TGF-β Induced Abnormal Expression Level of DNA Methyltransferase and Related miRNA During Neonatal Rat Colon Tissue Culture
下载PDF
导出
摘要 目的建立大鼠(乳鼠)肠上皮组织体外培养实验体系,检测TGF-β干预后大肠组织DNA甲基转移酶(DNA methyltransferase,Dnmt)及相关mi RNA表达的变化,研究TGF-β诱导上皮组织的相关机制。方法取出生3天的SD大鼠大肠组织建立体外组织块培养体系,观察组织块生长的情况,再用10 ng/ml TGF-β干预组织生长,对比干预前后组织生长状况的变化,并在干预不同的时间取组织样本;HE染色观察组织结构变化,提取组织块中RNA,采用RT-PCR方法检测DNA甲基转移酶及其相关mi RNA的表达水平变化。结果 TGF-β处理不同时间的组织块HE染色分析结果表明,在培养过程中,组织基本结构逐渐不能保持。对Dnmts及相关mi RNA的表达水平检测结果表明,TGF-β干预组织后,Dnmts及相关mi RNA的表达水平异常,相应升高或降低;在TGF-β干预过程中,使用甲基转移酶抑制剂5-Aza-d C干预24 h后,Dnmts的表达水平下降至无法检出,而此时相关mi RNA的表达水平相应升高,甚至恢复至接近无TGF-β干预状态。结论组织块培养过程中加入TGF-β干预,组织块的生长情况、Dnmts及相关mi RNA的表达水平表现出异常,甲基化转移酶抑制剂能够抑制Dnmts的表达并且调节mi RNA异常表达。 Objective To build an in vitro neonatal rat epithelial tissue culture system, to detect the expression level of DNA methyltransferase(Dnmt) and relevant mi RNA in the cultured tissues, and to investigate related mechanism of induction effect of TGF-beta during colon tissue culture. Methods We applied 3-day-old SD rat's intestinal tissues to build the in vitro tissue culture system and observed the growth state, added 10ng/ml TGF-beta in culture system to induce the growth of cultured tissues. The tissues from different time were collected in the experiment and the morphological change of the tissues was observed by HE staining through microscope. The expression levels of DNA methyltransferase and related mi RNA were detected by reverse transcription(RT)-PCR. Results Slices of the tissues from different time were fi xed, embedded and stained with Hematoxylin and Eosin. The morphology of the cultured tissues was changed as the extension of the culture time and the epithelial structure gradually disintegrated. RT-PCR results showed that after treated with 10ng/ml TGF-beta, the expression levels of Dnmts and relevant mi RNA were abnormal; Dnmts expression were up-regulated or down-regulated; after TGF-β and 5-Aza-d C interference, the express level of Dnmts couldn't be detected; meanwhile the relevant mi RNA expression level was up-regulated, even close to untreated status. Conclusion TGF-β could infl uence the growth of colon tissues, lead to the abnormal expression levels of Dnmts and relevant mi RNA; 5-Aza-d C inhibits the expression of Dnmts and regulates the abnormal expression of mi RNA.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第3期169-174,共6页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金资助项目(81173257)
关键词 TGF-Β 大肠癌发生 DNA甲基转移酶 MIRNA TGF-β Colorectal tumorigenesis DNA methyltransferase(Dnmt) miRNA
  • 相关文献

参考文献28

  • 1Laconi E. The evolving concept of tumor microenvironments[J].Bioessays, 2007, 29(8): 738-44.
  • 2Papageorgis P, Stylianopoulos T. Role of TGFbeta in regulation ofthe tumor microenvironment and drug delivery (Review)[J]. Int JOncol, 2015, 46(3): 933-43.
  • 3Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in thetumour microenvironment[J]. Nat Rev Cancer, 2013, 13(11):78,8-99.
  • 4Khin SS, Kitazawa R, Kondo T, et al. Epigenetic alteration byDNA promoter hypermethylation of genes related to transforminggrowth factor-β(TGF-β) signaling in cancer[J]. Cancers (Basel),20,11, 3(1): 982-93.
  • 5Klose RJ, Bird AP. Genomic DNA methylation: the mark and itsmediators[J]. Trends Biochem Sci, 2006, 31(2): 89-97.
  • 6Han L, Witmer PD, Casey E, et al. DNA methylation regulatesMicroRNA expression[J]. Cancer Biol Ther, 2007, 6(8): 1284-8.
  • 7Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-amechanism for early oncogenic pathway addiction[J]. Nat RevCancer, 2006, 6(2): 107-16.
  • 8陈晓娟,闫少春,邵国.人DNA甲基化转移酶的分类及其功能[J].包头医学院学报,2014,30(4):136-138. 被引量:5
  • 9张丽丽,吴建新.DNA甲基化——肿瘤产生的一种表观遗传学机制[J].遗传,2006,28(7):880-885. 被引量:55
  • 10满朝来,唐高霞,赵丽,李凤,甄鑫.DNA甲基化与microRNA[J].中国生物工程杂志,2014,34(8):81-87. 被引量:3

二级参考文献145

  • 1Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sar- gent D,Ford R,Dancey J,Arbuck S,Gwyther S,Mooney M, Rubinstein L,Shankar L,Dodd L,Kaplan R,Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
  • 2Varallyay CG,Muldoon LL,Gahramanov S,Wu YJ,Good- man JA,Li X,Pike MM,Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009; 29: 853-860.
  • 3Young H,Baum R,Cremerius U,Herholz K,Hoekstra O, Lammertsma AA,Pruim J,Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxy- glucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Re- search and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
  • 4Adam R,Avisar E,Ariche A,Giachetti S,Azoulay D,Casta- ing D,Kunstlinger F,Levi F,Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
  • 5Scheele J,Stang R,Altendorf-Hofmann A,Paul M. Resection of colorectal liver metastases. World J Surg ; 19: 59-71.
  • 6Power DG,Kemeny NE. Role of adjuvant therapy after re- section of colorectal cancer liver metastases. J Clin Oncol 2010;28: 2300-2309.
  • 7Adam R,Pascal G,Castaing D,Azoulay D,Delvart V,Paule B,Levi F,Bismuth H. Tumor progression while on chemo- therapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discus- sion 1052-1061.
  • 8Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T, Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Hol- mgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F. Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
  • 9Kabbinavar F,Hurwitz HI,Fehrenbacher L,Meropol NJ, Novotny WF,Lieberman G,Griffing S,Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
  • 10Malavasi N,Ponti G,Depenni R,Bertolini F,Zironi S,Luppi G,Conte PF. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol 2009; 2: 35.

共引文献75

同被引文献18

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部